Skip to content

AbCellera Biologics Inc. ABCL Net Investment in Lease

Net Investment in Lease at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
Precigen logo
PrecigenPGEN
Zymeworks logo
ZymeworksZYME
ADMA Biologics logo
ADMA BiologicsADMA

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.72B+59.2%
Enterprise value$1.76B+100.0%
P/S21.7×-25.0×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s net investment in lease?
AbCellera Biologics Inc. (ABCL) reported net investment in lease of $134.3M in Q1 2026.
How has AbCellera Biologics Inc.'s net investment in lease changed year-over-year?
AbCellera Biologics Inc.'s net investment in lease increased by 95.4% year-over-year, from $68.74M to $134.3M.
What is the long-term trend for AbCellera Biologics Inc.'s net investment in lease?
Over 2 years (2023 to 2025), AbCellera Biologics Inc.'s net investment in lease has grown at a 36.4% compound annual growth rate (CAGR), from $73.14M to $136.12M.